Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(6 sites)

China

Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong

Henan Cancer Hospital, Zhengzhou, Henan

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei

Hubei Cancer Hospital, Wuhan, Hubei

Hunan Cancer Hospital, Changsha, Hunan

The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang